Gerald Segal is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 25 publications with 5,009 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
265 N Broadway St
Portland, OR 972271800
Telephone
503-280-1223Registry record last updated 18 Jan 2012.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.4%CD38-directed Cytolytic Antibody84.1%Daratumumab100%Part B, office-administered≥12 patientsThalidomide Analog0.9%Revlimid45%Pomalyst32%Lenalidomide23%Part D<11 patients+ 5 more classes in this area
Sensory organs
5.1%Corticosteroid5.1%Dexamethasone sodium phosphate95%Dexamethasone5%Part D + Part B≥15 patientsMetabolism & gastrointestinal
3.5%Serotonin-3 Receptor Antagonist2.6%Granisetron hydrochloride88%Ondansetron Odt8%Ondansetron Hcl4%Part D + Part B<11 patientsAntidiarrheal microorganisms0.3%Folic Acid100%Part D≥13 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1992–1994 per NIH RePORTER. The latest:
- DISSECTING THE HEMATOPOIETIC GROWTH FACTOR NETWORK
Oregon Health and Science University
FY1994R29DK043375 - DISSECTING THE HEMATOPOIETIC GROWTH FACTOR NETWORK
Oregon Health and Science University
FY1993R29DK043375 - DISSECTING THE HEMATOPOIETIC GROWTH FACTOR NETWORK
Oregon Health and Science University
FY1992R29DK043375
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report
Transplantation Proceedings
2015 - Endothelial Vesicles in an Allograft Kidney Biopsy: An Unusual Pattern of Biclonal Paraprotein Deposition
American Journal of Clinical Pathology
2014
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”